Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates

Shahida Baqar, Louis Bourgeois, Peter J. Schultheiss, Richard I. Walker, David M. Rollins, Richard L. Haberberger, Olgerts R. Pavlovskis

Research output: Contribution to journalArticle

Abstract

The safety and immunogenicity of two prototype oral Campylobacter killed whole-cell (CWC) vaccines were tested in rhesus monkeys. Animals were immunized with a primary two-dose series (days 0 and 14) of vaccine consisting of CWC (1010 particles/dose) given alone or in combination with 0.5-1000 μg of the heat-labile enterotoxin of Escherichia coli as an oral adjuvant (OA). A booster vaccination, 4 weeks after primary immunization, was given to animals receiving CWC alone or supplemented with 0.5, 5 or 50 μg of OA. Both CWC and CWC-OA were well tolerated, with no adverse side-effects noted. Campylobacter-specific as well as adjuvant-specific antibody-secreting cells (ASCs) were determined in peripheral blood collected 7 days after each vaccine dose. Campylobacter-specific IgA ASC responses were enhanced by OA in a dose-dependent manner (p = 0.025), while IgG ASC responses were not. Seroconversions (both IgA and IgG) to Campylobacter antigens were also enhanced in monkeys receiving adjuvanted vaccine. No significant booster vaccination effect was observed in circulating ASCs in any of the immunization groups. In vitro T-cell proliferative responses to Campylobacter jejuni antigens were somewhat enhanced in both the CWC and CWC-OA immunization groups. These results demonstrate that CWC-OA is safe and superior to CWC alone in its ability to stimulate both local and systemic Campylobacter-specific IgA and IgG responses in primates and they support its further evaluation in human clinical studies.

Original languageEnglish (US)
Pages (from-to)22-28
Number of pages7
JournalVaccine
Volume13
Issue number1
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Inactivated Vaccines
Campylobacter
prototypes
Primates
adjuvants
mouth
immune response
vaccines
Safety
Antibody-Producing Cells
cells
Vaccines
Immunoglobulin A
Immunization
immunization
antibodies
Immunoglobulin G
dosage
Vaccination
antigens

Keywords

  • Campylobacter vaccine
  • heat-labile Escherichia coli enterotoxin
  • primates

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Immunology
  • Microbiology
  • Virology

Cite this

Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. / Baqar, Shahida; Bourgeois, Louis; Schultheiss, Peter J.; Walker, Richard I.; Rollins, David M.; Haberberger, Richard L.; Pavlovskis, Olgerts R.

In: Vaccine, Vol. 13, No. 1, 1995, p. 22-28.

Research output: Contribution to journalArticle

Baqar, Shahida ; Bourgeois, Louis ; Schultheiss, Peter J. ; Walker, Richard I. ; Rollins, David M. ; Haberberger, Richard L. ; Pavlovskis, Olgerts R. / Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. In: Vaccine. 1995 ; Vol. 13, No. 1. pp. 22-28.
@article{b8cd280acd6549e4beae1866ccf766c2,
title = "Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates",
abstract = "The safety and immunogenicity of two prototype oral Campylobacter killed whole-cell (CWC) vaccines were tested in rhesus monkeys. Animals were immunized with a primary two-dose series (days 0 and 14) of vaccine consisting of CWC (1010 particles/dose) given alone or in combination with 0.5-1000 μg of the heat-labile enterotoxin of Escherichia coli as an oral adjuvant (OA). A booster vaccination, 4 weeks after primary immunization, was given to animals receiving CWC alone or supplemented with 0.5, 5 or 50 μg of OA. Both CWC and CWC-OA were well tolerated, with no adverse side-effects noted. Campylobacter-specific as well as adjuvant-specific antibody-secreting cells (ASCs) were determined in peripheral blood collected 7 days after each vaccine dose. Campylobacter-specific IgA ASC responses were enhanced by OA in a dose-dependent manner (p = 0.025), while IgG ASC responses were not. Seroconversions (both IgA and IgG) to Campylobacter antigens were also enhanced in monkeys receiving adjuvanted vaccine. No significant booster vaccination effect was observed in circulating ASCs in any of the immunization groups. In vitro T-cell proliferative responses to Campylobacter jejuni antigens were somewhat enhanced in both the CWC and CWC-OA immunization groups. These results demonstrate that CWC-OA is safe and superior to CWC alone in its ability to stimulate both local and systemic Campylobacter-specific IgA and IgG responses in primates and they support its further evaluation in human clinical studies.",
keywords = "Campylobacter vaccine, heat-labile Escherichia coli enterotoxin, primates",
author = "Shahida Baqar and Louis Bourgeois and Schultheiss, {Peter J.} and Walker, {Richard I.} and Rollins, {David M.} and Haberberger, {Richard L.} and Pavlovskis, {Olgerts R.}",
year = "1995",
doi = "10.1016/0264-410X(95)80006-Y",
language = "English (US)",
volume = "13",
pages = "22--28",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates

AU - Baqar, Shahida

AU - Bourgeois, Louis

AU - Schultheiss, Peter J.

AU - Walker, Richard I.

AU - Rollins, David M.

AU - Haberberger, Richard L.

AU - Pavlovskis, Olgerts R.

PY - 1995

Y1 - 1995

N2 - The safety and immunogenicity of two prototype oral Campylobacter killed whole-cell (CWC) vaccines were tested in rhesus monkeys. Animals were immunized with a primary two-dose series (days 0 and 14) of vaccine consisting of CWC (1010 particles/dose) given alone or in combination with 0.5-1000 μg of the heat-labile enterotoxin of Escherichia coli as an oral adjuvant (OA). A booster vaccination, 4 weeks after primary immunization, was given to animals receiving CWC alone or supplemented with 0.5, 5 or 50 μg of OA. Both CWC and CWC-OA were well tolerated, with no adverse side-effects noted. Campylobacter-specific as well as adjuvant-specific antibody-secreting cells (ASCs) were determined in peripheral blood collected 7 days after each vaccine dose. Campylobacter-specific IgA ASC responses were enhanced by OA in a dose-dependent manner (p = 0.025), while IgG ASC responses were not. Seroconversions (both IgA and IgG) to Campylobacter antigens were also enhanced in monkeys receiving adjuvanted vaccine. No significant booster vaccination effect was observed in circulating ASCs in any of the immunization groups. In vitro T-cell proliferative responses to Campylobacter jejuni antigens were somewhat enhanced in both the CWC and CWC-OA immunization groups. These results demonstrate that CWC-OA is safe and superior to CWC alone in its ability to stimulate both local and systemic Campylobacter-specific IgA and IgG responses in primates and they support its further evaluation in human clinical studies.

AB - The safety and immunogenicity of two prototype oral Campylobacter killed whole-cell (CWC) vaccines were tested in rhesus monkeys. Animals were immunized with a primary two-dose series (days 0 and 14) of vaccine consisting of CWC (1010 particles/dose) given alone or in combination with 0.5-1000 μg of the heat-labile enterotoxin of Escherichia coli as an oral adjuvant (OA). A booster vaccination, 4 weeks after primary immunization, was given to animals receiving CWC alone or supplemented with 0.5, 5 or 50 μg of OA. Both CWC and CWC-OA were well tolerated, with no adverse side-effects noted. Campylobacter-specific as well as adjuvant-specific antibody-secreting cells (ASCs) were determined in peripheral blood collected 7 days after each vaccine dose. Campylobacter-specific IgA ASC responses were enhanced by OA in a dose-dependent manner (p = 0.025), while IgG ASC responses were not. Seroconversions (both IgA and IgG) to Campylobacter antigens were also enhanced in monkeys receiving adjuvanted vaccine. No significant booster vaccination effect was observed in circulating ASCs in any of the immunization groups. In vitro T-cell proliferative responses to Campylobacter jejuni antigens were somewhat enhanced in both the CWC and CWC-OA immunization groups. These results demonstrate that CWC-OA is safe and superior to CWC alone in its ability to stimulate both local and systemic Campylobacter-specific IgA and IgG responses in primates and they support its further evaluation in human clinical studies.

KW - Campylobacter vaccine

KW - heat-labile Escherichia coli enterotoxin

KW - primates

UR - http://www.scopus.com/inward/record.url?scp=0028819184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028819184&partnerID=8YFLogxK

U2 - 10.1016/0264-410X(95)80006-Y

DO - 10.1016/0264-410X(95)80006-Y

M3 - Article

VL - 13

SP - 22

EP - 28

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 1

ER -